首页> 外文期刊>Fertility and Sterility: Official Journal of the American Fertility Society, Pacific Coast Fertility Society, and the Canadian Fertility and Andrology Society >Intrauterine injection of human chorionic gonadotropin before embryo transfer significantly improves the implantation and pregnancy rates in in vitro fertilization/intracytoplasmic sperm injection: a prospective randomized study.
【24h】

Intrauterine injection of human chorionic gonadotropin before embryo transfer significantly improves the implantation and pregnancy rates in in vitro fertilization/intracytoplasmic sperm injection: a prospective randomized study.

机译:胚胎移植前宫腔注射人绒毛膜促性腺激素可显着提高体外受精/胞浆内精子注射的着床率和妊娠率:一项前瞻性随机研究。

获取原文
获取原文并翻译 | 示例
           

摘要

OBJECTIVE: To investigate the value of intrauterine injection of human chorionic gonadotropin (hCG) before embryo transfer (ET). DESIGN: Prospective randomized study. SETTING: The Egyptian IVF-ET Center. PATIENT(S): Infertility patients younger than 40 years undergoing their first in vitro fertilization/intracytoplasmic sperm injection (IVF-ICSI). INTERVENTION(S): The study group (n = 167) received either 100 IU of hCG (n = 83), or 200 IU of hCG (n = 84) via intrauterine administration before ET. The control group (n = 93) underwent ET without hCG. After the interim analysis, the modified study group (n = 107) received intrauterine injection of 500 IU of hCG, and the control group (n = 105) underwent ET without hCG. MAIN OUTCOME MEASURE(S): Clinical pregnancy rate (PR) and implantation rate (IR). RESULT(S): The IR and PR were statistically significantly higher in the 500 hCG group (41.6% and 75%, respectively) as compared with the control group (29.5% and 60%, respectively). The IR and PR were 26.6% and 54% in the 100 hCG group, 28.3% and 57% in the 200 IU hCG group, and 29.4% and 60% in the control group, respectively, with no statistically significant difference. CONCLUSION(S): Intrauterine injection of 500 IU of hCG before ET statistically significantly improved the implantation and pregnancy rates in IVF/ICSI. CLINICAL TRIALS.GOV NUMBER: NCT 01030393.
机译:目的:探讨子宫内注射绒毛膜促性腺激素(hCG)在胚胎移植(ET)前的价值。设计:前瞻性随机研究。地点:埃及IVF-ET中心。患者:年龄小于40岁的不育患者首次接受体外受精/胞浆内精子注射(IVF-ICSI)。干预:研究组(n = 167)在ET之前通过宫内给药接受了100 IU hCG(n = 83)或200 IU hCG(n = 84)。对照组(n = 93)接受无hCG的ET。经过中期分析后,改良的研究组(n = 107)接受宫内注射500 IU的hCG,对照组(n = 105)接受了无hCG的ET。主要观察指标:临床妊娠率(PR)和植入率(IR)。结果:500 hCG组的IR和PR在统计学上显着高于对照组(分别为29.5%和60%)(分别为41.6%和75%)。 100 hCG组的IR和PR分别为26.6%和54%,200 IU hCG组的28.3%和57%,对照组的29.4%和60%,无统计学差异。结论:ET前宫腔内注射500 IU的hCG在统计学上显着改善了IVF / ICSI的着床率和妊娠率。临床试验编号:NCT 01030393。

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号